WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone,1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. “This advancement re

Company plans to resubmit BLA to the FDA in June 2026ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New

Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanisms Adcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab COPENHAGEN, Denmark, May 26, 2026 /PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high u

LOS ANGELES--(BUSINESS WIRE)--BioTools Innovator (BTI), the first accelerator focused exclusively on life science tools and diagnostics startups, has selected 30 companies for its 2026 Accelerator program. These startups will participate in a four-month program offering in-depth, personalized mentorship from senior industry leaders, access to funding opportunities, and meaningful engagement with peers and expert advisors. Chosen from a highly competitive pool of nearly 550 applicants, the select

Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection BETHESDA, Md., May 26, 2026 /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly. Vaccine Company's proprietary In Vivo Nanopartic

Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease INDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies,

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medi

SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare Conference Wednesday, June 3rd, 2026 at 7:35 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D.

BOSTON, May 26, 2026 /PRNewswire/ -- ZETA SURGICAL today announced the first commercial deployment of its FDA-cleared Zeta TMS Navigation System. The system will be utilized at HOPE Therapeutics in West Palm Beach, Florida, to deliver high-precision navigated Transcranial Magnetic Stimulation (TMS) for the treatment of Major Depressive Disorder and other neurological conditions. Continue Reading Zeta Navigation System TMS is a non-invasive therapy primarily used for treatment-resistant depressio